HealthDay News — More than 69% of Medicaid enrollees with a new diagnosis of opioid use disorder (OUD) do not receive treatment within 180 days, according to a study published online November 23 in ...

HealthDay News — A confidential internal memo from the US Food and Drug Administration (FDA) is creating new controversy around vaccine safety after an agency official said the COVID-19 vaccine may ...

Intensive behavioral therapy also recommended, including setting physical exercise and diet goals, energy intake restriction, weekly counseling.

ST-503 is a one-time dose, investigational epigenetic regulator that specifically targets and silences the SCN9A gene.

Zilganersen is an investigational antisense oligonucleotide designed to block the product of excess GFAP caused by mutations in the GFAP gene.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for baxdrostat for the add-on treatment of uncontrolled or treatment resistant hypertension in ...